+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Genomics and proteomics are changing discovery, development and clinical use of dementia drugs

Genomics and proteomics are changing discovery, development and clinical use of dementia drugs

Expert Opinion on Drug Discovery 2(3): 313-319

Drug discovery as well as the optimization of drug use in dementia is at the verge of a new stage, which is being brought about by the broad and systematic application of functional genomics and proteomics. Alzheimer's disease is the focus of this transition, whereas vascular dementia can benefit from the spill over from cardiovascular research, which is already more developed. This review discusses the stratification of Alzheimer's patients for cholinesterase inhibitor therapy according to genetic polymorphisms and the modulating roles of mutations in the genes coding for angiotensin-converting enzyme, presenilin, cathepsin and potassium channels, which are all hotbeds for 'omics' applications. Lastly, the case for humanin is discussed as an example of the discovery of a potentially novel neuroprotective pathway that could be exploited for dementia drugs.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053400295

Download citation: RISBibTeXText

PMID: 23484643

DOI: 10.1517/17460441.2.3.313

Related references

Genomics and proteomics: the new millennium of drug discovery and development. Journal of Pharmacological and Toxicological Methods 44(1): 291-300, 2001

Genomics and proteomics: The new millennium of drug discovery and development. Journal of Pharmacological & Toxicological Methods 44(1): 291-300, July-August, 2000

The application of proteomics and genomics in drug discovery and development. Molecular & Cellular Proteomics 2(7 Suppl.): S81, 2003

Application of genomics, proteomics and metabolomics in drug discovery, development and clinic. Therapeutic Delivery 4(3): 395-413, 2013

Discovery informatics Integrating genomics and proteomics for drug discovery. Abstracts of Papers American Chemical Society 224(1-2): COMP 3, 2002

The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science. Korean Journal of Laboratory Medicine 31(2): 61-71, 2011

Chemical genomics tools in the discovery and development of cancer therapeutics drugs. International Journal of Cancer Suppl. (13): 323-324, 2002

New drug discovery in the postgenomic era: from genomics to proteomics. Journal of Clinical Psychiatry 61(12): 894-895, 2000

Comparative genomics and proteomics in drug discovery. 2007

Proteomics and genomics: perspectives on drug and target discovery. Current Opinion in Chemical Biology 12(1): 1-3, 2008

Application of genomics and proteomics in drug target discovery. Genetics and Molecular Research 13(1): 198-204, 2014

Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?. Behavioral and Brain Functions 5: 2, 2009

Blood-brain barrier genomics, proteomics, and new transporter discovery. Neurorx 2(1): 151-161, 2005

Yeast genomics and proteomics in drug discovery and target validation. Progress in Cell Cycle Research 5: 159-166, 2003

Connecting research discovery with care delivery in dementia: the development of the Indianapolis Discovery Network for Dementia. Clinical Interventions in Aging 7: 509-516, 2012